OPKO 10-Q Details Q3 Loss, $403M Cash and BioReference Held-for-Sale Ahead of $722M Labcorp Deal
OPK sits 67% above its 52-week low of $0.977.
Summary
OPKO's Q3 10-Q shows continuing-operations revenue of $65.4 million (up 16%) but a $35.6 million quarterly loss, $403.2 million of cash, and the remaining BioReference lab business booked as held for sale pending the $722.0 million Labcorp deal.
Key Events · Earnings and Guidance · OPK
-
Q3 Revenue Up 16%, Loss Persists
Continuing-operations revenue rose to $65.4 million from $56.4 million, but the company still lost $35.6 million from continuing operations in the quarter and $91.2 million in the first nine months.
-
BioReference Booked as Held for Sale
The remaining clinical and anatomic pathology business sits in the disposal group at $248.1 million of assets against $9.4 million of liabilities, with the Labcorp Asset Purchase Agreement signed October 14, 2026 for $722.0 million cash plus up to $150.0 million of 4Kscore earnout.
-
Cash Cushion After Royalty Upsizing
Cash, cash equivalents and restricted cash totaled $403.2 million at September 30, 2026, after the August 13, 2026 amendment added $125.0 million of 2044 Royalty Financing Notes (now $375.0 million) secured partly by Eli Lilly Mazdutide royalties.
-
Buybacks Continue Despite Cash Burn
OPKO repurchased 20,835,105 shares for $28.4 million in the first nine months at an average $1.37, including 7,050,000 shares for $10.5 million in Q3 at an average $1.49, leaving $84.3 million of program capacity.
Analysis · OPK · Life Sciences
The headline numbers were already out this afternoon, but the full 10-Q is where the balance sheet actually gets stress-tested. Continuing operations lost $35.6 million in the quarter and $91.2 million in the first nine months, funded largely by $403.2 million of cash and restricted cash after the $125 million royalty-note upsizing in August. The bigger structural fact is that BioReference's remaining lab business is now formally held for sale — $248.1 million of assets on the block for $722.0 million cash from Labcorp, plus up to $150.0 million of 4Kscore earnout — which converts a cash-burning diagnostics segment into a near-term liquidity event. Against that, the company kept buying back stock ($28.4 million in nine months at an average $1.37) while still burning cash, and the Israeli Tax Authority's roughly $246 million assessment remains an unresolved overhang. The Labcorp closing (outside date April 14, 2027, pending HSR clearance) is the event that determines whether the remaining Global Products and Innovative Biotech platforms are funded comfortably or need another raise.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OPK was trading at $1.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $0.98 to $1.81. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.